ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Design, synthesis, and biological evaluation of pentacyclic triterpenoids-triphenylphosphine derivatives as antibacterial agents to combat MRSA.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we aimed to design and synthesize a series of pentacyclic triterpenoids-triphenylphosphine (TPP) derivatives. A total of 22 derivatives were systematically synthesized and evaluated for their in vitro antibacterial activities against four pathogenic strains, namely, S. aureus, MRSA, E. coli, and P. aeruginosa, using the standard broth microdilution method. Notably, most derivatives demonstrated better antibacterial activity than the pentacyclic triterpenoids parent nucleus. Among them, Compound 1 performed the most potent antibacterial activity on MRSA (MIC = 0.78 μM), which was significantly better than norfloxacin, penicillin, tobramycin, and tetracycline at the same concentration. In addition, according to the results of hemolysis test, chick chorioallantoic membrane (CAM) assay, zebrafish toxicity test, and acute toxicity test, Compound 1 exhibited higher selectivity and biosafety. Finally, the mechanistic results suggested that Compound 1 may exert its antibacterial activity by acting on key targets such as SasG, IcaB, and MurQ, thereby affecting the biofilm formation process.
Indexed as
Identifiers
42437828What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.